scholarly journals Risk factors for hepatocellular carcinoma and its incidence after interferon treatment in patients with chronic hepatitis C

Hepatology ◽  
1998 ◽  
Vol 27 (5) ◽  
pp. 1394-1402 ◽  
Author(s):  
Akinori Kasahara ◽  
Norio Hayashi ◽  
Kiyoshi Mochizuki ◽  
Masahide Takayanagi ◽  
Kentaro Yoshioka ◽  
...  
Surgery Today ◽  
1996 ◽  
Vol 26 (2) ◽  
pp. 126-130 ◽  
Author(s):  
Atsuyoshi Onitsuka ◽  
Naoki Yamada ◽  
Hiroyuki Yasuda ◽  
Tomoyuki Miyata ◽  
Toshimi Kachi

1999 ◽  
Vol 11 (1) ◽  
pp. 24-31 ◽  
Author(s):  
Takao SHIBAYAMA ◽  
Shin‐iciro MORI ◽  
Hiroo OHTAKE ◽  
Seishuu HAYASHI ◽  
Shunichi SAEKI ◽  
...  

2009 ◽  
Vol 104 ◽  
pp. S135
Author(s):  
Kaoru Kikuchi ◽  
Yutaka Yamaguchi ◽  
Yukio Yosida ◽  
Kenji Chinen ◽  
Tomiaki Kubota ◽  
...  

2005 ◽  
Vol 40 (2) ◽  
pp. 148-156 ◽  
Author(s):  
Masafumi Ikeda ◽  
Shigetoshi Fujiyama ◽  
Motohiko Tanaka ◽  
Michio Sata ◽  
Tatsuya Ide ◽  
...  

2000 ◽  
Vol 14 (suppl b) ◽  
pp. 63B-67B
Author(s):  
Andreas Schüler ◽  
Michael Peter Manns

The decision to treat a patient with chronic hepatitis C (CHC) is based on what is known about the risk factors for developing liver cirrhosis or hepatocellular carcinoma, as well as on conditions that contraindicate therapy or impair therapy effectiveness. Several factors, including age, treatment side effects, disease severity, concurrent diseases and life conditions, may render treatment decisions more difficult. This review focuses on identifying CHC patients who should not receive treatment.


Sign in / Sign up

Export Citation Format

Share Document